In this Drug Safety Update document, “Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies”, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) took new regulatory action regarding the Xeljanz risk of cardiovascular events as well as the Xeljanz risk of cancers, or malignancies.
Issued by the MHRA on October 6, 2021, this document states that Xeljanz should not be used by these patients in the groups identified below unless there is no suitable drug treatment alternative:
- people older than 65 years of age;
- people who are current or past smokers;
- people with other cardiovascular risk factors, such as diabetes or coronary artery disease;
- people with pre-existing cancer or malignancy risk factors.
About the Xeljanz risk of cardiovascular events, we find this important information in the October 2021 MHRA Xeljanz document:
Predictive factors for development of myocardial infarction (fatal and non-fatal) were identified using a multivariate Cox model with backward selection. These factors were age older than 65 years, male sex, current or past smoking, history of diabetes, and history of coronary artery disease (which includes past myocardial infarction, coronary heart disease, stable angina pectoris, or past coronary artery procedures).
And about the Xeljanz risk of cancers, that document provides this information:
Predictive factors for development of malignancies (excluding non-melanoma skin cancer) were identified using a multivariate Cox model with backward selection. These were age older than 65 years and current or past smoking.
We will watch for possible additional drug regulatory actions due to the Xeljanz risk of cardiovascular events as well as the Xeljanz risk of cancers, and report significant developments here.
Our law firm is handling Xeljanz drug injury lawsuits for patients with cases of Xeljanz causing heart problems such as heart attacks, strokes, pulmonary embolism (PE), and deep vein thrombosis (DVT), as well as Xeljanz causing lymphoma, lung cancer, and other cancers.[View article at original source]